ERBB2 and non-small cell lung carcinoma: Mutations of the human epidermal growth factor receptor 2 gene (HER2, also known as ERBB2) have also been identified as oncogenic drivers in NSCLC with a frequency of 2% to 3%, with most such mutations consisting of a 12-bp in-frame insertion (encoding YVMA) in exon 20 [15–17].